16B10-MMAF

16B10-MMAF is an **antibody-drug conjugate (ADC)** consisting of the monoclonal antibody 16B10, which specifically targets the pro-transforming growth factor alpha (proTGFα) protein present on some tumor cells, conjugated to the cytotoxic **payload monomethyl auristatin F (MMAF)** via a linker. The mechanism of action relies on binding to membrane-bound proTGFα on target cells, internalization of the ADC, and lysosomal cleavage to release MMAF, which then disrupts tubulin polymerization, resulting in mitotic arrest and subsequent cell death. The antitumor action of 16B10-MMAF is highly dependent on target (proTGFα) expression, with marked efficacy in preclinical tumor models and induction of G2/M phase cell cycle arrest and apoptosis in vitro and in vivo. Efficacy appears to be augmented by the presence of the EGFR. The developer appears to be an academic or research institution, as clinical-stage or commercial partners are not identified in the published literature[1].